-
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis. Curr Med Res Opin. 2025 Dec; 41(12):2323-2338. Coombs CC, Woyach JA, Brown JR, Ghia P, Roeker LE, Patel K, Eyre TA, Tam CS, Seymour JF, Shah NN, Flinn I, Cheah CY, Ma S, Rhodes JM, Izutsu K, Jurczak W, Wierda WG, Hess LM, Bhandari NR, Loubert A, Abada PB, Lamanna N. PMID: 41612863.
-
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study. Blood Adv. 2026 Jan 16. Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani CS, Hoffmann MS, Cheah CY, Munir T, Lewis DJ, Scarfò L, Eyre TA, Alencar AJ, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada PB, Balbas M, Zinzani PLL. PMID: 41544219.
-
BETting on the future: BET inhibition for patients with lymphoma. Med. 2026 Jan 09; 7(1):100955. Voorhees TJ, Coombs CC. PMID: 41519111.
-
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. Blood Adv. 2025 Dec 09; 9(23):5954-5964. Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY. PMID: 40845254; PMCID: PMC12686794.
-
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2026 Feb 20; 44(6):476-485. Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovská A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Özcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG. PMID: 41353787; PMCID: PMC12904240.
-
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2025 Nov; 21(26):3435-3445. Ibrahim S, Pham N, Sahni A, Sekeres S, Cool A, Taylor J, Coombs CC. PMID: 41042631; PMCID: PMC12582124.
-
What's hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of non-hematologic cancers. Haematologica. 2025 Sep 04. Martínez JC, Coombs CC. PMID: 40905095.
-
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025 Sep; 43(25):2841. Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. PMID: 40729625.
-
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025 Aug 10; 43(23):2658. Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. PMID: 40577663.
-
R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Dec; 25(12):e1014-e1021. Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Brem EA, Van Etten RA, Nelson EL, Coombs CC, Chan A. PMID: 40681431.
-
Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2025 Aug; 31(8):494-504. Kharfan-Dabaja MA, Kumar A, Pinilla-Ibarz J, Brown JR, Shadman M, Awan FT, Kenderian SS, Siddiqi T, Abramson JS, Al-Juhaishi T, Brander DM, Coombs CC, Furman RR, Jain N, Khan N, Saba NS, Collins JM, Beitinjaneh A, Stephens DM, Woyach J, Hamadani M. PMID: 40514010.
-
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025 Aug; 43(22):2538-2549. Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. PMID: 40479620; PMCID: PMC12288890.
-
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective. Clin Lymphoma Myeloma Leuk. 2025 Sep; 25(9):e663-e667. Stephens DM, Stewart C, Avruch L, Coombs CC, Danilov A, Hill B, Shadman M, Gerrie A, Jensen CE, Hoffmann M, Winter A, Ermann DA, Barr PM, O'Brien S, Koffman B, Byrd JC. PMID: 40483257.
-
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2025 Mar 11; 9(5):1213-1229. Soumerai JD, Barrientos J, Ahn I, Coombs C, Gladstone D, Hoffman M, Kittai A, Jacobs R, Lipsky A, Patel K, Rhodes J, Skarbnik A, Thompson M, Ermann D, Reville P, Shah H, Brown JR, Stephens DM. PMID: 39561376; PMCID: PMC11993837.
-
Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Clin Lymphoma Myeloma Leuk. 2025 Jun; 25(6):e366-e373. Danilov AV, Sauter C, Phillips T, Coombs CC, Ip A, Wang Y, Rhodes J, Leslie L, Barrientos J, Saeed H, Strati P, Barta SK, Shadman M. PMID: 39919997.
-
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025 Jan 01; 110(1):92-102. Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR. PMID: 39363864; PMCID: PMC11694105.
-
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study. Am J Hematol. 2025 Mar; 100(3):511-515. Ghosh N, Eyre TA, Brown JR, Lamanna N, Manzoor BS, Coombs CC, Tuncer HH, Ujjani C, Leslie LA, Roeker LE, Davids MS, Rhodes JM, Skarbnik AP, Sinai W, Fleury I, Hill BT, Martinez-Calle N, Barr PM, Jawaid D, Emechebe N, Pearson L, Lansigan F, Choi Y, Jensen CE, Fakhri B, Stephens DM, Marx SE, Schuster SJ, Coyle M, Pivneva I, Watson T, Guerin A, Shadman M. PMID: 39698781; PMCID: PMC11803543.
-
Interindividual variability in CYP3A-mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia. Clin Transl Sci. 2024 Dec; 17(12):e70106. Lee J, Beers JL, Cheng I, Truong V, Brown Z, Muluneh B, Coombs CC, Jackson KD. PMID: 39673246; PMCID: PMC11645475.
-
Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044. Xie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan AM, Bewersdorf JP, Mendez L, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana Yi C, Osman AEG, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. PMID: 38996210; PMCID: PMC11561536.
-
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201). Clin Cancer Res. 2024 Nov 01; 30(21):4910-4919. Jensen JL, Bobek O, Chan ICC, Miller BC, Hillman DW, Heller G, Druley T, Armstrong AJ, Morris MJ, Milowsky MI, Beltran H, Bolton KL, Coombs CC. PMID: 39287426; PMCID: PMC11539927.
-
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386. Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. PMID: 38861666; PMCID: PMC11451378.
-
Clonal hematopoiesis of indeterminate potential and cardiovascular disease: Pathogenesis, clinical presentation, and future directions. Prog Cardiovasc Dis. 2024 Sep-Oct; 86:79-85. Gajagowni S, Hopkins S, Qadeer Y, Virani SS, Verdonschot JAJ, Coombs CC, Amos CI, Nead KT, Jaiswal S, Krittanawong C. PMID: 39278303.
-
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. PMID: 39033770.
-
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197. Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. PMID: 38824917; PMCID: PMC11617602.
-
Are we closer to a standard of care for Richter's syndrome? Novel treatments on the horizon. Expert Rev Hematol. 2024 Apr-May; 17(4-5):117-126. Pham N, Coombs CC, O'Brien S. PMID: 38693662.
-
Frontline Therapy of CLL-Changing Treatment Paradigms. Curr Hematol Malig Rep. 2024 04; 19(2):65-74. Coombs CC. PMID: 38337108.
-
Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms. Leuk Lymphoma. 2024 Feb; 65(2):209-218. Johnson SM, Haberberger J, Galeotti J, Ramkissoon L, Coombs CC, Richardson DR, Foster MC, Duncan D, Montgomery ND, Ferguson NL, Zeidner JF. PMID: 37921062.
-
SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2023 10; 23(10):697-704. Easaw S, Ezzati S, Coombs CC. PMID: 37544810.
-
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 07 06; 389(1):33-44. Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W. PMID: 37407001.
-
A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease. Blood Cancer J. 2023 06 26; 13(1):96. Johnson SM, Haberberger J, Galeotti J, Ramkissoon L, Coombs CC, Richardson DR, Foster MC, Duncan D, Zeidner JF, Ferguson NL, Montgomery ND. PMID: 37365170; PMCID: PMC10293251.
-
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):515-526. Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR. PMID: 37076367.
-
Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant. Cancers (Basel). 2023 Mar 18; 15(6). Coombs CC, Easaw S, Grover NS, O'Brien SM. PMID: 36980726; PMCID: PMC10046903.
-
Clonal Hematopoiesis and the Heart: a Toxic Relationship. Curr Oncol Rep. 2023 05; 25(5):455-463. Jensen JL, Easaw S, Anderson T, Varma Y, Zhang J, Jensen BC, Coombs CC. PMID: 36920637; PMCID: PMC10015145.
-
Noncovalent BTK inhibitors in B-cell lymphoma. Clin Adv Hematol Oncol. 2023 02; 21(2):100-103. Coombs CC. PMID: 36780476.
-
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022 08 09; 6(15):4553-4557. Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovic M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. PMID: 35736670; PMCID: PMC9636322.
-
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. Blood Rev. 2022 11; 56:100986. Meier J, Jensen JL, Dittus C, Coombs CC, Rubinstein S. PMID: 35753868; PMCID: PMC12606726.
-
The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 2022; 13:20406207221101697. Jensen JL, Mato AR, Pena C, Roeker LE, Coombs CC. PMID: 35747462; PMCID: PMC9210100.
-
Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome. Leuk Lymphoma. 2022 08; 63(8):1831-1838. Cozad M, Stump SE, Buhlinger K, Collins J, Muir M, Coombs CC, Muluneh B. PMID: 35262457.
-
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2022 08; 63(8):1823-1830. Collins J, Stump SE, Heiling H, Muir M, Deal A, Proco D, Nguyen C, Cozad M, Mato A, Coombs CC, Muluneh B. PMID: 35249442.
-
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med. 2022 02 24; 386(8):735-743. Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. PMID: 35196427; PMCID: PMC9074143.
-
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 02 15; 28(4):603-608. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. PMID: 34789482; PMCID: PMC9253788.
-
Advances in chronic lymphocytic leukemia from the 63rd American Society of Hematology Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol. 2022 02; 20 Suppl 7(2):15-19. Coombs CC. PMID: 35343945.
-
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood. 2021 11 04; 138(18):1768-1773. Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu J, Patten PEM, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik A, Kamdar M, Jacobs R, Walter H, Walewska R, Broom A, Lebowitz S, Isaac KM, Portell CA, Ahn IE, Ujjani CS, Shadman M, Skånland SS, Chong EA, Mato AR. PMID: 34297826; PMCID: PMC8313815.
-
Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting. Prostate. 2022 02; 82(2):169-181. Miyahira AK, Zarif JC, Coombs CC, Flavell RR, Russo JW, Zaidi S, Zhao D, Zhao SG, Pienta KJ, Soule HR. PMID: 34734426; PMCID: PMC8688282.
-
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discov. 2021 Nov; 2(6):616-629. Zeidner JF, Vincent BG, Ivanova A, Moore D, McKinnon KP, Wilkinson AD, Mukhopadhyay R, Mazziotta F, Knaus HA, Foster MC, Coombs CC, Jamieson K, Van Deventer H, Webster JA, Prince GT, DeZern AE, Smith BD, Levis MJ, Montgomery ND, Luznik L, Serody JS, Gojo I. PMID: 34778801; PMCID: PMC8580622.
-
Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Transplant Cell Ther. 2021 12; 27(12):1021.e1-1021.e5. Tschernia NP, Kumar V, Moore DT, Vincent BG, Coombs CC, Van Deventer H, Foster MC, DeZern AE, Luznik L, Riches ML, Serody JS, Gojo I, Zeidner JF. PMID: 34474164.
-
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 12; 35(12):3542-3550. Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. PMID: 34172893; PMCID: PMC8632688.
-
Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment. Leuk Lymphoma. 2021 12; 62(12):3035-3038. Ramkissoon LA, Buhlinger K, Nichols A, Coombs CC, Foster MC, Galeotti J, Kaiser-Rogers K, Richardson DR, Montgomery ND, Zeidner JF. PMID: 34151687.
-
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. PMID: 33676628; PMCID: PMC11758240.
-
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia. Am J Hematol. 2021 04 01; 96(4):462-470. Richardson DR, Swoboda DM, Moore DT, Johnson SM, Chan O, Galeotti J, Esparza S, Hussaini MO, Van Deventer H, Foster MC, Coombs CC, Montgomery ND, Sallman DA, Zeidner JF. PMID: 33502020; PMCID: PMC10284351.
-
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica. 2021 01 01; 106(1):284-287. Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, Islam P, Whitaker K, Coombs CC, Tuncer HH, Pagel JM, Jacobs R, Winter AM, Bailey N, Sitlinger A, Schuh AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR. PMID: 32079693; PMCID: PMC7776352.
-
Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia. J Adv Pract Oncol. 2021 Jan-Feb; 12(1):20-28. Garner LM, Kline T, Miller J, Deal A, Zhu A, Sketch MR, Coombs CC, Muluneh B. PMID: 33552659; PMCID: PMC7844188.
-
Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020 11; 52(11):1219-1226. Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. PMID: 33106634; PMCID: PMC7891089.
-
Philadelphia Chromosome-positive Acute Myeloid Leukemia With e1a3 BCR-ABL1 Fusion Transcript. Hemasphere. 2020 Dec; 4(6):e484. Sheets JW, Eulitt P, He R, Olteanu H, Coombs CC, Foster MC, Montgomery ND, Zeidner JF. PMID: 33134868; PMCID: PMC7566865.
-
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989. Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR. PMID: 32841336; PMCID: PMC7448605.
-
Chasing ctDNA in Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2020 May; 40:e351-e360. Coombs CC, Dickherber T, Crompton BD. PMID: 32598183.
-
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020 07 15; 26(14):3589-3596. Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Yazdy MS, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. PMID: 32198151; PMCID: PMC8588795.
-
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. Leukemia. 2020 06; 34(6):1563-1576. Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I. PMID: 31900407; PMCID: PMC7272276.
-
Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia. Semin Oncol Nurs. 2019 12; 35(6):150957. Richardson DR, Foster MC, Coombs CC, Zeidner JF. PMID: 31759819; PMCID: PMC10246438.
-
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020 03; 188(6):918-923. Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR. PMID: 31682002; PMCID: PMC7528953.
-
Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia. Br J Haematol. 2020 01; 188(1):173-177. Esparza S, Muluneh B, Galeotti J, Matson M, Richardson DR, Montgomery ND, Coombs CC, Jamieson K, Foster MC, Zeidner JF. PMID: 31621058; PMCID: PMC7574315.
-
Myeloid sarcoma manifesting as generalized lymphadenopathy in a patient with myelofibrosis. Clin Case Rep. 2019 Nov; 7(11):2274-2276. Trennepohl C, Sorah J, Eulitt P, Galeotti J, Zeidner JF, Montgomery ND, Coombs CC. PMID: 31788302; PMCID: PMC6878033.
-
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 03 15; 26(6):1247-1257. Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. PMID: 31527168; PMCID: PMC7528620.
-
Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia. Hemasphere. 2019 10; 3(4):e292. Johnson SM, Richardson DR, Galeotti J, Esparza S, Zhu A, Fedoriw Y, Weck KE, Foster MC, Coombs CC, Zeidner JF, Montgomery ND. PMID: 31942545; PMCID: PMC6919468.
-
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019 05 28; 3(10):1568-1573. Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. PMID: 31101647; PMCID: PMC6538868.
-
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270. Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. PMID: 31004001; PMCID: PMC8020996.
-
Managing Clonal Hematopoiesis in Patients With Solid Tumors. J Clin Oncol. 2019 01 01; 37(1):7-11. Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E. PMID: 30403571; PMCID: PMC6354773.
-
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncol. 2018 11 01; 4(11):1589-1593. Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, Solit DB, Baselga J, Arcila ME, Ladanyi M, Zhang L, Levine RL, Berger MF, Zehir A. PMID: 29872864; PMCID: PMC6224316.
-
Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival. J Clin Endocrinol Metab. 2018 11 01; 103(11):4216-4223. Boucai L, Falcone J, Ukena J, Coombs CC, Zehir A, Ptashkin R, Berger MF, Levine RL, Fagin JA. PMID: 30137527; PMCID: PMC6194804.
-
Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations. Br J Haematol. 2019 02; 184(4):496. Galeotti J, Coombs CC. PMID: 30334576.
-
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clin Cancer Res. 2018 12 01; 24(23):5918-5924. Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, Montgomery ND, Bolton KL, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp HS, Levine RL, Papaemmanuil E, Zehir A, Hayes DN, Padron E. PMID: 29866652; PMCID: PMC6812550.
-
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine. 2018 May; 31:174-181. Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. PMID: 29728305; PMCID: PMC6013781.
-
Maternal Malignancy Evaluation After Discordant Cell-Free DNA Results. Obstet Gynecol. 2018 03; 131(3):464-468. Carlson LM, Hardisty E, Coombs CC, Vora NL. PMID: 29420407; PMCID: PMC5823781.
-
Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently. Am J Hematol. 2018 08; 93(4):595-596. Coombs CC, Mathews SP. PMID: 29052253.
-
Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. J Thromb Thrombolysis. 2017 Nov; 44(4):489-493. Coombs C, Kuk D, Devlin S, Siegelbaum RH, Durack JC, Parameswaran R, Mantha S, Deng K, Soff G. PMID: 28993967.
-
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell. 2017 09 07; 21(3):374-382.e4. Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Ladanyi M, Tallman MS, Levine RL, Berger MF. PMID: 28803919; PMCID: PMC5591073.
-
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 11; 101(11):e457-e460. Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. PMID: 27418649; PMCID: PMC5394875.
-
Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol. 2016 May; 13(5):305-18. Coombs CC, Tallman MS, Levine RL. PMID: 26620272; PMCID: PMC5525060.
-
Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):146-51. Coombs CC, DeAngelis LM, Feusner JH, Rowe JM, Tallman MS. PMID: 26724834; PMCID: PMC5028896.
-
Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015 Apr 17; 5:e304. Coombs CC, Tavakkoli M, Tallman MS. PMID: 25885425; PMCID: PMC4450325.
-
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer. 2013 Sep 01; 119(17):3177-85. Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, Wierda WG, Ferrajoli A. PMID: 24022787; PMCID: PMC4394603.
-
Chronic lymphocytic leukemia in African Americans. Leuk Lymphoma. 2012 Nov; 53(11):2326-9. Coombs CC, Falchi L, Weinberg JB, Ferrajoli A, Lanasa MC. PMID: 22646816.
-
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood. 2012 Aug 23; 120(8):1687-90. Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC. PMID: 22745306; PMCID: PMC3429309.
US